AVEO Pharmaceuticals EBITDA Margin 2009-2021 | AVEO

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for AVEO Pharmaceuticals (AVEO) over the last 10 years. The current EBITDA margin for AVEO Pharmaceuticals as of September 30, 2021 is .
AVEO Pharmaceuticals EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2021-09-30 $0.03B $-0.06B -215.38%
2021-06-30 $0.02B $-0.06B -366.67%
2021-03-31 $0.01B $-0.05B -587.50%
2020-12-31 $0.01B $-0.04B -557.14%
2020-09-30 $0.01B $-0.03B -471.43%
2020-06-30 $0.03B $-0.01B -20.69%
2020-03-31 $0.03B $-0.00B -13.79%
2019-12-31 $0.03B $-0.00B -3.33%
2019-09-30 $0.03B 0 0.00%
2019-06-30 $0.01B $-0.02B -400.00%
2019-03-31 $0.01B $-0.03B -520.00%
2018-12-31 $0.00B $-0.03B -625.00%
2018-09-30 $0.00B $-0.03B -966.67%
2018-06-30 $0.01B $-0.03B -433.33%
2018-03-31 $0.01B $-0.03B -466.67%
2017-12-31 $0.01B $-0.03B -362.50%
2017-09-30 $0.01B $-0.03B -350.00%
2017-06-30 $0.00B $-0.03B -800.00%
2017-03-31 $0.00B $-0.03B -750.00%
2016-12-31 $0.00B $-0.03B -1450.00%
2016-09-30 $0.01B $-0.03B -433.33%
2016-06-30 $0.02B $-0.01B -55.00%
2016-03-31 $0.02B $-0.00B -20.00%
2015-12-31 $0.02B $-0.00B -10.53%
2015-09-30 $0.02B $-0.01B -40.00%
2015-06-30 $0.00B $-0.03B -2800.00%
2015-03-31 $0.00B $-0.05B -1500.00%
2014-12-31 $0.02B $-0.05B -250.00%
2014-09-30 $0.02B $-0.05B -277.78%
2014-06-30 $0.02B $-0.06B -347.06%
2014-03-31 $0.02B $-0.07B -480.00%
2013-12-31 $0.00B $-0.10B inf%
2013-09-30 $0.02B $-0.10B -650.00%
2013-06-30 $0.02B $-0.11B -647.06%
2013-03-31 $0.02B $-0.11B -568.42%
2012-12-31 $0.02B $-0.11B -540.00%
2012-09-30 $0.01B $-0.11B -2220.00%
2012-06-30 $0.01B $-0.10B -1300.00%
2012-03-31 $0.03B $-0.08B -242.42%
2011-12-31 $0.17B $0.04B 23.49%
2011-09-30 $0.18B $0.05B 29.94%
2011-06-30 $0.18B $0.06B 31.84%
2011-03-31 $0.17B $0.05B 27.98%
2010-12-31 $0.05B $-0.05B -120.00%
2010-09-30 $0.04B $-0.06B -141.03%
2010-06-30 $0.04B $-0.05B -130.77%
2010-03-31 $0.03B $-0.05B -164.29%
2009-12-31 $0.02B $-0.04B -190.48%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.223B $0.006B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09